Keywords
Lenalidomide
Dexamethasone
New diagnosis
Multiple myeloma
Submitted : 2022-08-06
Accepted : 2022-08-21
Published : 2022-09-05
Abstract
Objective: To investigate the clinical effects of combining bortezomib with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Methods: This study was conducted in Shaanxi Provincial People’s Hospital from January 2020 to January 2022. 25 patients were selected for the study and divided into two groups: 12 patients in one group, the control group, were treated with bortezomib and thalidomide in combination with dexamethasone, and 13 patients in the other group were treated with bortezomib and dexamethasone. The other group of 13 patients, given bortezomib combined with lenalidomide and dexamethasone, was named as the experimental group, and the treatment effects of the two groups were compared and analyzed. Results: Comparing the treatment efficiency of the two groups, the incidence of patients in the experimental group was 92.31%, which was significantly higher than that of the control group (33.33%), with a significant difference, indicated as P<0.05. At the same time, the incidence of adverse reactions in the experimental group was lower, the clinical index scores were closer to normal values, and the level of inflammatory response was lower, with significant differences in all data in the control group (P < 0.05), and the experimental group had better treatment results. Conclusion: Bortezomib combined with lenalidomide and dexamethasone is clinically effective in the treatment of newly diagnosed patients with multiple myeloma, and is of positive significance in promoting recovery.
References
Lu J, Zhu XJ, 2020, Clinical Efficacy and Toxic Side Effects of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma. Hebei Medicine, 26(4): 537–540.
Xu J, Cao YJ, Du J, et al., 2020, New Targets and Therapeutic Strategies in Multiple Myeloma Research—A Report on the Hot Topics of the 17th International Symposium on Myeloma. Journal of Translational Medicine, 9(3): 181–184.
Wang X, Xu K-L, 2020, Application of Multi-Targeted CAR-T Cell Therapy in Relapsed Refractory Multiple Myeloma. Journal of Clinical Hematology, 33(7): 446–450.
Zhang Y, ZM, 2022, Clinical Efficacy of Bortezomib Combined with Lenalidomide and Dexamethasone (VRD) Regimen and Bortezomib Combined with Thalidomide and Dexamethasone (VTD) Regimen in the Treatment of Multiple Myeloma. Systemic Medicine, 7(1): 102–105.
Gu X, Yin S, Zhao F, et al., 2020 Efficacy of Bortezomib Combined with Lenalidomide and Dexamethasone in the Treatment of Multiple Myeloma. Journal of Aerospace Medicine, 31(11): 1353–1354.
Tang Q, 2020, Clinical Effects of Bortezomib Combined with Dexamethasone and Thalidomide in The Treatment of Primary Multiple Myeloma. Clinical Medicine Research and Practice, 5(4): 39 + 40 + 76.
Ouyang X, Luo P, Hu F, et al., 2021, Analysis of Bortezomib and Thalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma in the Elderly. Jiangxi Medicine, 56(1): 57–58 + 74.
Fan L, Ma YP, Zhang M, et al., 2020, Meta-Analysis of the Efficacy of Lenalidomide in the Treatment of Patients with Multiple Myeloma and Its Associated Serious Infections. International Journal of Blood Transfusion and Hematology, 43(1): 34–42.
Ding X, Chen J, Wang W, et al., 2021, A Case of Multiple Myeloma with Tumor Lysis Syndrome Treated with Isazomib and Review of The Literature. Chinese Rural Medicine, 28(16): 41 + 42.
Liu J, He HY, Li L, et al., Efficacy and Safety of Daratumumab for Relapsed/Refractory Multiple Myeloma. Chinese Journal of Hematology, 42(1): 27–32.
Jing L, Lan XJ, 2020, Efficacy and Safety of Lenalidomide Combined with Low-Dose Dexamethasone in the Treatment of Multiple Myeloma in the Elderly. Primary Care Forum, 24(4): 492–493.
Wang G, 2021, Analysis of the Effective Value of Using Lenalidomide in Combination with Low-Dose Dexamethasone in the Treatment of Relapsed Refractory Multiple Myeloma. Northern Pharmacology, 18(6):125–126.
Lv P, 2020, Clinical Observation of Lenalidomide Combined with Cyclophosphamide and Low-dose Dexamethasone in the Treatment of Multiple Myeloma. China Practical Medicine, 15(3): 145 + 146.
Guo Q, Wang J, Liu Y, et al., 2021, Effect of Lenalidomide on Autologous Transplantation of Hematopoietic Stem Cells in Patients with Multiple Myeloma. Journal of Clinical Military Medicine, 49(1): 37–39 + 43.
Li J, 2020, Effectiveness and Prognosis of Lenalidomide Combined with VAD Regimen in the Treatment of Multiple Myeloma. Clinical Medicine, 40(9): 92–94.
Zhao GX, Cheng Z, Wei RH, et al., 2022, A Case of Chimeric Antigen Receptor T Cells Combined with Lenalidomide for the Treatment of Grade 3 Refractory Multiple Myeloma After Chimeric Antigen Receptor T Cell Therapy and Review of the Literature. Leukemia-Lymphoma, 31(02): 122–124.
Zhao GX, Cheng Z, Wei RH, et al., 2021, A Case of Relapsed Refractory Multiple Myeloma Treated with Lenalidomide Combined with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells and Review of the Literature. Leukemia; Lymphoma, 30(4): 224–227.
Sun H, Du Y, Xu LZ, et al., 2020, Correlation of CD56 and CD117 Expression Levels with the Efficacy of Lenalidomide in the Treatment of Multiple Myeloma. Modern Biomedical Advances, 20(1): 72–75.
Jiang W, Luo P, 2021, Clinical Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma. Journal of Clinical Rational Drug Use, 14(21): 30–32.
Luo M, Hu LW, Gu XK, et al., 2021, Clinical Efficacy and Prognosis of Long-Term Maintenance Treatment with Lenalidomide in Patients with Multiple Myeloma. Chinese Journal of Experimental Hematology, 29(2): 540–546.